SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to discussions around a potential $2 billion offering and insider selling, sparking debate about dilution and the company's valuation. While some community members view the offering as bullish, citing a premium price and warrants, others express concern about a potential bubble and the impact on existing shareholders. The conversation also includes comparisons to other quantum computing stocks and broader market trends.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to positive earnings, a raised price target from Needham, and news of a massive AI lease deal with CoreWeave. The community is discussing the potential for a short squeeze and future hyperscaler deals, with some bulls projecting significant gains while bears warn of overvaluation. Overall, sentiment is bullish, driven by the company's growth in the AI data center space.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, igniting discussions about future government contracts. The community is actively evaluating the company's growth potential relative to other quantum computing stocks. Many investors are describing LAES as undervalued with potential for a significant upward trajectory.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss the potential for a short squeeze, fueled by high short interest and recent positive developments, including a partnership with Google. Community members are closely monitoring resistance levels and anticipating a breakout, drawing comparisons to other AI and high-performance computing data center plays. The focus remains on the company's transition towards AI infrastructure and its potential for growth in the sector.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as traders debate whether its recent surge is justified by fundamentals or fueled by a short squeeze, with community members highlighting both bullish and bearish arguments.  The launch of a new 2x short ETF (RGTZ) has added another layer to the discussion, as some believe it will exacerbate the squeeze while others see it as a sign of an impending reversal.  Quantum computing stocks are also in focus, and the community is comparing RGTI's valuation and potential against competitors.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors react to recent news, including a new multi-launch agreement with Japan's iQPS. The community is actively discussing the potential impact of this deal, along with speculation about upcoming catalysts like the Neutron launch and potential government contracts. Some traders caution about short-term overvaluation, while long-term bulls remain confident in the company's growth prospects.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as discussions revolve around its potential to catch up with other miners like CLSK and IREN, with some expressing frustration over its underperformance and management. Community members are debating whether its current valuation reflects its Bitcoin holdings and future AI prospects. Short interest remains high, fueling speculation about a potential squeeze.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is surging, fueled by speculation around a potential ETF and positive technical indicators, leading to renewed interest in the crypto asset. The community is actively discussing price targets and potential breakouts, while also debating whether this rally will be sustained. Some traders are pointing to Litecoin's historical performance relative to Bitcoin, suggesting it is undervalued.

One & One Green Technologies, Inc. engages in the recycle, production and trade of scrap metals. Its products include copper alloy ingot, aluminum scrapes, and plastic beads. The company was founded on April 17, 2024 and is headquartered in Bulacan, Philippines.

One and one Green Technologies. Inc - Ordinary Shares - Class A

Fueled by its recent IPO, $YDDL is trending due to significant after-hours volatility and a low float, leading to speculation of a potential massive run. The stock's connection to AI and green technology is adding to the excitement, though some traders express concerns about it being a pump and dump. Community members are actively discussing potential price targets and whether the stock can maintain its momentum.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as traders discuss its potential in the quantum computing sector, particularly compared to peers like $IONQ and $RGTI. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and a potential for significant upside, while some anticipate a near-term run to $30+ and compare it to previous high-flying SPACs. Chatter also mentions upcoming events and presentations, further fueling interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

Equity

Shares of Illumina, Inc. (ILMN) rose 6% on Wednesday afternoon after the biotechnology company announced the launch of a new business called BioInsight to accelerate data-driven drug discovery. &nbsp;The new business within the company will focus on developing data assets, software, and artificial intelligence to fuel drug development. It will be led by company veteran Rami Mehio as Senior Vice President and General Manager.BioInsight will bring together strengths across DNA sequencing, data analysis, software, and AI to help customers identify drug targets, understand biological pathways, and discover novel disease mechanisms, Illumina <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=bac27a69-7339-4f9f-9c1e-1fbc262895d4">said</a>."BioInsight, under Rami's guidance, will strengthen Illumina's leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development," said CEO Jacob Thaysen.The key focus areas of the new business will be working with large national initiatives and industry partners to enable large-scale genetic and biological data generation projects, as well as developing software solutions to analyze multimodal data. It will also focus on developing AI tools through strategic partnerships to build an ecosystem for large-scale multimodal data analysis, in addition to providing platforms to enable private and secure data access for research and pharmaceutical partners.Mehio noted the dramatic reduction in sequencing costs, coupled with a rise in AI capabilities, is changing how biological insights are derived, and the company is now focused on turning this data into meaningful discoveries.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ILMN">ILMN stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_01_at_1_55_41_PM_png_e0f82bb5f8.webp" alt="ILMN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Oct. 01, 2025 | Source: Stocktwits" width="622" height="60"><figcaption>ILMN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Oct. 01, 2025 | Source: Stocktwits</figcaption></figure>ILMN stock is down by 24% this year and by approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/byd-reports-5.5-percent-sales-decline-in-september/chCYJzjR3aH">BYD Reports 5.5% Sales Decline In September</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Illumina Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Illumina Stock Surged 6% Today – Here’s Why

The company announced that its new business will focus on developing data assets, software, and artificial intelligence to drive drug development.

VF Corp (VFC) announced on Monday that they have entered into a definitive agreement for Bluestar Alliance to acquire the Dickies brand for $600 million in cash.The company said that the transaction is expected to close by the end of calendar year 2025. Shares of VF Corp traded over 2% higher in Monday’s pre-market session.Retail sentiment on <a href="https://stocktwits.com/symbol/VFC">VF Corp</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.Dickies&nbsp;is an American brand that offers clothing primarily in the workwear and streetwear categories, with distribution in 55 countries. “Since 1922, Dickies&nbsp;has provided hard-wearing, long-lasting and comfortable clothes, cementing its status as a storied brand in performance workwear,” said Joseph Gabbay, CEO of Bluestar Alliance, a brand management firm.VF Corp’s CEO Bracken Darrell said he was “confident” that under Bluestar Alliance’s ownership, Dickies will continue to improve and realize its significant growth potential. “As I’ve said before, we continuously evaluate our portfolio and this transaction will enable us to bring our net debt level down and will be accretive to our growth on a pro-forma basis,” Darrell said.VF Corp has been undergoing a turnaround under Darrell, with the company having trimmed jobs and also looking to reduce costs by selling some brands. It is also seeing costs related to the Trump administration’s tariffs on global trading partners. In July, the company noted that the incremental annualized tariff impact would be between $100 million and $120 million, down from its prior estimate of $150 million.Shares of VF Corp have declined nearly 31% this year and have fallen over 18% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">Tesla Shares Surge As Elon Musk Discloses First Stock Purchase In Open Market Since 2020: Report</a>

In this photo illustration, the VF Corporation company logo is seen displayed on a smartphone screen.

VF Corp To Sell Dickies Brand To Bluestar Alliance For $600M

VF Corp said that the transaction is expected to close by the end of calendar year 2025.

The Campbell’s Company (CPB) experienced multiple price target hikes from Wall Street on Thursday, with TD Cowen citing that the packaged food maker’s annual profit guidance was less negative than initially feared, due to an acceleration of cost savings and near-term tariff mitigation.TD Cowen raised its price target to $31 from $29 and maintained a ‘Hold’ rating, according to TheFly. The firm added that the company’s fourth-quarter results were all better than expected.Retail sentiment on <a href="https://stocktwits.com/symbol/CPB">Campbell’s</a> remained unchanged in the ‘bullish’ territory, with chatter at ‘extremely high’ levels, according to data from Stocktwits. The retail user message count on the stock jumped 175% in the last 24 hours, as of Thursday morning, and shares of the firm were down nearly 3% during midday trading.<figure class="image"><img style="aspect-ratio:806/96;" src="https://news.stocktwits-cdn.com/CPB_sentiment_png_a93adb3d63.webp" alt="CPB sentiment.png" width="806" height="96"><figcaption>CPB sentiment and message volume September 4, 2025, as of 1:50 pm ET | Source: Stocktwits</figcaption></figure>Bernstein also raised its price target on Campbell's to $39 from $38 and kept an ‘Outperform’ rating. The firm noted that Campbell's seems to be doing the right things to get the portfolio moving again, investing in brand support and innovation, and fueling these investments with stepped-up productivity improvements.On Wednesday, CEO Mick Beekhuizen stated that consumers remain cautious and are being intentional with their spending, a trend that is expected to persist amid price increases resulting from the Trump administration’s tariffs, which are anticipated to slow demand for goods across the discretionary and consumables categories.Bernstein added that while snack category dynamics remain sluggish, management expects this portfolio to stabilize by the second half of 2026, noting that it's encouraging to see the recent success of more premium products, such as Milano cookies.Campbell’s shares have declined nearly 22% this year and fallen over 36% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/giii-apparel-ceo-says-company-absorbing-some-tariff-costs/chwdfxyRdYz">G-III Apparel CEO Says Company Absorbing Some Tariff Costs To Stay Competitive, Gain Market Share</a>

Prego brand spaghetti sauce in glass jars. (Source: Getty Images)

Campbell’s Gains Wall Street Confidence With Multiple Price Target Hikes, Retail Chatter Surges

Bernstein raised its price target on Campbell's to $39 from $38 and noted that the company appears to be taking the right steps to revitalize the portfolio, investing in brand support and innovation.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday said that it has approved Biogen Inc.’s (BIIB) Zuranolone to treat moderate or severe postnatal depression (PPD) in adults following childbirth.Postnatal depression is a type of depression that many parents experience after having a baby and is marked by feelings of sadness, irritability, anxiety, loss of interest, extreme fatigue, appetite changes, among others. One in every ten women is affected by postnatal depression within a year of childbirth, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gov.uk/government/news/mhra-approves-zuranolone-to-treat-postnatal-depression-in-adults-following-childbirth">per </a>MHRA.Biogen’s Zuranolone, under the brand name Zurzuvae, is the first oral treatment for postnatal depression approved in the UK, the agency said.The drug comes as a capsule and should be taken orally at night with a fat-containing meal for 14 days. Common side effects of the medicine include memory impairment, confusion, and fatigue, among others.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> trended within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Zurzuvae last month in the European Union. The drug was approved by the U.S. Food and Drug Administration in 2023. According to Biogen, an estimated 5-20% of women with a pregnancy experience symptoms of PPD in Europe.Zurzuvae was discovered by Sage Therapeutics Inc. (SAGE). In 2020, Biogen and Sage Therapeutics entered into a collaboration to jointly develop and commercialize Zurzuvae in the U.S. As part of the agreement, Biogen received exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.In the second quarter, Biogen reported revenue of $46.4 million from Zurzuvae, up from $14.9 million in the corresponding quarter of 2024, driven by increased demand.BIIB stock is down by 10% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-suncar-technology-stock-rallying-today/chsUeO7RdlB">Why Is SunCar Technology Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression

Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said. 

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea drug. The firm, however, kept a ‘Buy’ rating on the shares.The near-term investor focus remains on Eylea and Eylea HD uptake, though Regeneron continues to deliver growth on its top and bottom line with Dupixent and Libtayo programs, the analyst told investors in a research note. On Stocktwits, retail sentiment around the stock trended in the ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1398/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_1_26_40_PM_png_155e98c160.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="1398" height="126"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A user further opined that the range of $400-$450 is a good entry point for the stock.<stembedurl>https://stocktwits.com/Johny34211/message/624597691</stembedurl>Eylea is approved to treat vision-threatening conditions that impact patients, such as diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and wet age-related macular degeneration (wAMD). Eylea HD, meanwhile, is a version of the drug that requires fewer injections.<a href="https://stocktwits.com/symbol/REGN">Regeneron</a> maintains exclusive rights to Eylea and Eylea HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of the two products. In the second quarter, total Eylea U.S. net sales decreased 25% to $1.15 billion, while Eylea HD U.S. net sales increased 29%.The company also said that it expects its regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration applications for Eylea HD, which were supposed to be decided on by August 2025.The anticipated delay, the company said, is related to observations from an FDA general site inspection at the filler for Eylea HD in these regulatory applications, Catalent Indiana LLC. This inspection was completed in mid-July and was not specific to Eylea HD. Novo Nordisk recently acquired Catalent.The company, however, expressed optimism for a quick resolution of the filling issues for Eylea HD, citing its progress with alternate third-party fillers and Novo Nordisk’s communications with the FDA.According to data from Koyfin, 16 of 24 analysts covering Regeneron rate it ‘Buy’ or higher, while seven rate it a ‘Hold,’ and one rates it a ‘Strong Sell.’The stock has an average price target of $708.91, representing an upside of about 28%.REGN stock is down by 22% this year and by about 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-drug-shows-improvement-in-sjogrens-disease-in-late-stage-trials/chrH2PLRde0">Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point

Truist, however, kept a ‘Buy’ rating on the shares.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s second-quarter earnings beat Wall Street expectations on Wednesday.Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. The analyst kept an ‘Overweight’ rating on the shares.The firm reiterated its confidence in the Elevidys franchise, noting that it sees an intact benefit-risk for ambulatory patients and potential upside from future updates on the non-ambulatory side.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> remained unmoved within ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_11_16_43_AM_png_bbc7e903bf.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the second-quarter sales number shows that the recent patient deaths did not undermine demand.<stembedurl>https://stocktwits.com/parbv/message/624138164</stembedurl>Another highlighted that Elevidys caters to a niche patient population not addressed by many others.<stembedurl>https://stocktwits.com/Bearcase/message/624132232</stembedurl>Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease primarily impacts boys.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals, CEO Doug Ingram said on Wednesday.For the second quarter, Sarepta reported total revenues of $611.1 million, above an analyst estimate of $531.04 million, owing to higher net product revenue of Elevidys. Adjusted and diluted earnings per share came in at $2.02, up from $0.43 in the corresponding quarter of 2024, and above an analyst estimate of $0.67.The company also said that it is on track to realize over $100 million in cost savings through the end of 2025 as part of the restructuring announced in July. SRPT stock is down by about 86% this year and by about 87% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/duolingo-stock-rockets-30-percent/chrm761Rd37">Duolingo Stock Rockets 30% And Retail Chatter Surges A Whopping 1,400% In 24 Hours: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. 

Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys

Shares of Sarepta Therapeutics Inc. (SRPT) traded 20% higher on Tuesday afternoon after the U.S. Food and Drug Administration (FDA) allowed the company to resume shipping Elevidys, its gene therapy for Duchenne muscular dystrophy, to children who are still able to walk.Elevidys is the first and only gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare and progressive condition that affects mainly boys and leads to loss of muscle function.Sarepta has been in a quagmire ever since the company reported the deaths of two patients treated with Elevidys from liver failure earlier this year.Sarepta had paused Elevidys' shipments last week to allow the FDA to complete a review of available safety information. The company is still in discussions with the FDA regarding an updated safety labeling on Elevidys. The pause on Elevidys for patients who cannot walk continues as the discussions linger on.On Monday, the company said that the death of an 8-year-old boy in Brazil was deemed unrelated to treatment with Elevidys by the FDA.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> is trending in the ‘extremely bullish’ territory, while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1354/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_2_20_10_PM_png_e1c2ee7b01.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits" width="1354" height="132"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits</figcaption></figure>After the hold was lifted on Monday, several analysts expressed relief or more concerns. &nbsp;JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. The FDA's recommendation to remove the voluntary pause of shipments of Elevidys in ambulatory patients is a "clear win" for the company, the analyst said.Bernstein, meanwhile, believes "it is only a matter of time before we learn of a death in an ambulatory patient that is deemed to be Elevidys-related."BMO Capital noted that while the financial overhang is partially removed with the lift of the hold, it expects a certain "hesitancy" from physicians and patients for Elevidys treatment in the near term.Barclays analyst Gena Wang, meanwhile, upgraded Sarepta to ‘Equal Weight’ from ‘Underweight’ with a price target of $22, up from $10. The suspension removal "removes the worst-case scenario" of a sustained period of Elevidys being off the market, and major liquidity risk is removed for now, it said, while adding that it is looking at greater FDA clarity.SRPT stock is down by 86% this year and by about 89% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-signs-up-timothee-chalamet-as-global-brand-ambassador/choaPQFR5yV">Lucid Signs Up Timothée Chalamet As Global Brand Ambassador: Retail Terms It A Desperate Cash-Draining Move</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Shares of Sarepta Therapeutics (SRPT) tumbled 14% on Friday after a patient reportedly died following treatment with one of the firm’s gene therapies, drawing concerns from Wall Street analysts.A company spokesperson <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy. Limb-girdle muscular dystrophy (LGMD) is a group of genetic conditions causing progressive muscle weakness and wasting, primarily affecting the muscles around the shoulders and hips.The company is already under pressure following the death of two patients following treatment with its gene therapy for Duchenne Muscular Dystrophy called Elevidys earlier this year.Following the news, Morgan Stanley analyst Michael Ulz said that the news adds to the ongoing safety concerns and near-term uncertainty around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a>.Leerink, meanwhile, opined that Sarepta management, knowing of a limb-girdle muscular dystrophy patient death in the trial and not disclosing it when announcing a restructuring earlier this week, is "deeply troubling and further undermines credibility."The firm added that it is “deeply disappointed in management's repeated execution missteps."While this is the first patient death reported in a limb-girdle muscular dystrophy trial, it is the third death reported by Sarepta this year across its gene therapy programs, William Blair told investors in a research note. Blair pointed out that Sarepta did not disclose the third patient death in its recent business update, which it termed "unfortunate and concerning.”Last month, the U.S. Food and Drug Administration said that it is probing the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Elevidys. The agency said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys and is evaluating the need for further regulatory action.Earlier this week, the company announced that it would eliminate 500 jobs, or approximately 36% of its workforce, as part of a restructuring effort aimed at achieving $400 million in annual cost savings. Sarepta also stated that it has agreed to the FDA’s request to include a black box warning in the ELEVIDYS label for acute liver injury and acute liver failure, to address the agency’s concerns regarding the use of the therapy in DMD patients who can walk.The company has halted shipments of the therapy to patients who cannot walk and is in talks with the FDA regarding a possible resumption.On Stocktwits, retail sentiment regarding Sarepta is trending in “extremely bullish” territory at the time of writing, accompanied by “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_18_at_10_54_58_AM_png_8b22d77332.webp" alt="SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits" width="628" height="63"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company destroyed the possibility of profitability or partnerships with the recent news.<stembedurl>https://stocktwits.com/Daily_Trader87/message/621494983</stembedurl>SRPT stock is down over 85% this year and by 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-chatter-on-bmy-doubles-in-24-hours-with-drug-failing-to-meet-primary-goal/ch8kA37R5qZ">Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier 

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.

Advisorshares Trust - AdvisorShares Dorsey Wright Short ETF -1x Shares

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$6.81
Prev Close	$6.83
Open	$6.83
Dividend Yield	N/A
50-Day Moving Average	$6.84
Beta	N/A
Avg. Volume	49,677.48
PE Ratio	N/A

52-Week High	$9.08
52-Week Low	$6.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DWSH
AdvisorShares Dorsey Wright Short ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DWSH News

DWSHAdvisorShares Dorsey Wright Short ETF